NASDAQ:LMAT - LeMaitre Vascular Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LeMaitre Vascular Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $35.31 -0.07 (-0.20 %) (As of 12/13/2019 11:43 AM ET) Add Compare Today's Range$35.09Now: $35.31▼$35.7450-Day Range$32.37MA: $34.83▼$35.9952-Week Range$21.79Now: $35.31▼$37.35Volume1,381 shsAverage Volume127,821 shsMarket Capitalization$705.85 millionP/E Ratio42.04Dividend Yield0.98%Beta1.21 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LMAT Previous Symbol CUSIPN/A CIK1158895 Webhttp://www.lemaitre.com/ Phone781-221-2266Debt Debt-to-Equity RatioN/A Current Ratio5.16 Quick Ratio3.26Price-To-Earnings Trailing P/E Ratio42.04 Forward P/E Ratio39.67 P/E Growth3.94 Sales & Book Value Annual Sales$105.57 million Price / Sales6.69 Cash Flow$1.11 per share Price / Cash Flow31.95 Book Value$6.65 per share Price / Book5.31Profitability EPS (Most Recent Fiscal Year)$0.84 Net Income$22.94 million Net Margins16.76% Return on Equity13.38% Return on Assets11.25%Miscellaneous EmployeesN/A Outstanding Shares19,990,000Market Cap$705.85 million Next Earnings Date2/18/2020 (Estimated) OptionableOptionable Receive LMAT News and Ratings via Email Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LMAT Rates by TradingView LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions What is LeMaitre Vascular's stock symbol? LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT." How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular? LeMaitre Vascular declared a quarterly dividend on Monday, October 21st. Investors of record on Wednesday, November 20th will be given a dividend of $0.085 per share on Thursday, December 5th. This represents a $0.34 annualized dividend and a dividend yield of 0.96%. The ex-dividend date of this dividend is Tuesday, November 19th. View LeMaitre Vascular's Dividend History. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular Inc (NASDAQ:LMAT) posted its quarterly earnings data on Wednesday, October, 23rd. The medical instruments supplier reported $0.25 EPS for the quarter, beating the consensus estimate of $0.21 by $0.04. The medical instruments supplier earned $29.10 million during the quarter, compared to the consensus estimate of $28.15 million. LeMaitre Vascular had a return on equity of 13.38% and a net margin of 16.76%. The company's revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 EPS. View LeMaitre Vascular's Earnings History. When is LeMaitre Vascular's next earnings date? LeMaitre Vascular is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for LeMaitre Vascular. What guidance has LeMaitre Vascular issued on next quarter's earnings? LeMaitre Vascular issued an update on its FY19 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share guidance of $0.88-0.90 for the period, compared to the Thomson Reuters consensus estimate of $0.85. The company issued revenue guidance of $117.2-118.0 million, compared to the consensus revenue estimate of $116.17 million. What price target have analysts set for LMAT? 4 equities research analysts have issued 1 year price objectives for LeMaitre Vascular's shares. Their forecasts range from $37.00 to $40.00. On average, they expect LeMaitre Vascular's share price to reach $39.00 in the next year. This suggests a possible upside of 10.4% from the stock's current price. View Analyst Price Targets for LeMaitre Vascular. What is the consensus analysts' recommendation for LeMaitre Vascular? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LeMaitre Vascular. What are Wall Street analysts saying about LeMaitre Vascular stock? Here are some recent quotes from research analysts about LeMaitre Vascular stock: 1. According to Zacks Investment Research, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (10/26/2019) 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on LMAT shares and are increasing our price target to $32 (from $30 previously) given the encouraging organic growth (and particularly the strong unit volume growth). We think margins will expand meaningfully (vs. Q1) for the remainder of FY/19 and step up again in FY/20 as recently-hired sale reps become increasingly productive. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now." (5/2/2019) Has LeMaitre Vascular been receiving favorable news coverage? Press coverage about LMAT stock has trended positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. LeMaitre Vascular earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for LeMaitre Vascular. Are investors shorting LeMaitre Vascular? LeMaitre Vascular saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 1,990,000 shares, an increase of 10.6% from the November 14th total of 1,800,000 shares. Based on an average trading volume of 125,600 shares, the days-to-cover ratio is presently 15.8 days. Currently, 12.1% of the shares of the stock are sold short. View LeMaitre Vascular's Current Options Chain. Who are some of LeMaitre Vascular's key competitors? Some companies that are related to LeMaitre Vascular include Glaukos (GKOS), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Atrion (ATRI), Tactile Systems Technology (TCMD), AtriCure (ATRC), Shockwave Medical (SWAV), Silk Road Medical (SILK), Cryolife (CRY), Luminex (LMNX), Orthofix Medical (OFIX), Antares Pharma (ATRS) and Anika Therapeutics (ANIK). What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include Canopy Growth (CGC), Sociedad Quimica y Minera de Chile (SQM), Aurora Cannabis (ACBFF), NVIDIA (NVDA), AbbVie (ABBV), Aurora Cannabis (ACB), Adobe (ADBE), Gilead Sciences (GILD), salesforce.com (CRM) and Teva Pharmaceutical Industries (TEVA). Who are LeMaitre Vascular's key executives? LeMaitre Vascular's management team includes the folowing people: Mr. George W. LeMaitre, Chairman & CEO (Age 54)Mr. David B. Roberts, Pres & Director (Age 55)Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 54)Mr. Trent G. Kamke, Sr. VP of Operations (Age 48)Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 85) Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's stock is owned by a number of of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (8.68%), State Street Corp (3.09%), Copeland Capital Management LLC (2.70%), Russell Investments Group Ltd. (1.82%), Summit Creek Advisors LLC (1.54%) and Rhumbline Advisers (0.76%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular. Which major investors are selling LeMaitre Vascular stock? LMAT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Conestoga Capital Advisors LLC, GW&K Investment Management LLC, Barclays PLC, Rice Hall James & Associates LLC, Curbstone Financial Management Corp and Commonwealth Equity Services LLC. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular. Which major investors are buying LeMaitre Vascular stock? LMAT stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Copeland Capital Management LLC, Summit Creek Advisors LLC, Rhumbline Advisers, Comerica Bank, Envestnet Asset Management Inc., Bridge City Capital LLC and Voya Investment Management LLC. View Insider Buying and Selling for LeMaitre Vascular. How do I buy shares of LeMaitre Vascular? Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is LeMaitre Vascular's stock price today? One share of LMAT stock can currently be purchased for approximately $35.32. How big of a company is LeMaitre Vascular? LeMaitre Vascular has a market capitalization of $706.05 million and generates $105.57 million in revenue each year. The medical instruments supplier earns $22.94 million in net income (profit) each year or $0.84 on an earnings per share basis. View Additional Information About LeMaitre Vascular. What is LeMaitre Vascular's official website? The official website for LeMaitre Vascular is http://www.lemaitre.com/. How can I contact LeMaitre Vascular? LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266. MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 406 (Vote Outperform)Underperform Votes: 290 (Vote Underperform)Total Votes: 696MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: What is FinTech?
